We use our own and third party cookies in order to inform you about our services, to ensure that we give you the best experience on our website and to know more about your navigation habits. If you accept cookies or if you continue using this site, we'll assume your consent to our use of these cookies. You can find more information and change your cookie settings in our Cookies Policy.

27.04.2018 12:21

ROVI Signs Licensing Agreement for the Middle East

Pharmaceutical company ROVI, which has a production plant in the Granada Health Science Technological Park (PTS), has signed a licensing agreement with multinational pharmaceutical group Hikma Pharmaceuticals PLC for the exclusive distribution and marketing of its enoxaparin biosimilar in 17 MENA (Middle East and North Africa) countries: Saudi Arabia, Jordan, Algeria, Egypt, Tunisia, Sudan, Syria, Yemen, Iraq, Oman, United Arab Emirates, Kuwait, Qatar, Bahrain, Libya, Palestine and Lebanon.


Inside the ROVI plant at the PTS.

ROVI’s enoxaparin sodium is a biosimilar to Sanofi’s Lovenox and Clexane, which are anticoagulant medications belonging to the low-molecular-weight heparin class. They are used to treat and prevent deep vein thrombosis and pulmonary embolism. As of 31 March 2018, ROVI had achieved national authorisation for its biosimilar of enoxaparin in 16 European markets, and has started marketing it in Germany and the United Kingdom. 

Juan López-Belmonte, ROVI Chief Executive Officer said, “ROVI is very excited to announce our recent agreement with Hikma, a global pharmaceutical company, with a strong presence across the MENA region. By leveraging Hikma’s strong local presence, patients across the region will be able to access our enoxaparin biosimilar. In this new phase, together with Hikma, we aim to expand ROVI’s global footprint and become a leader in the low-molecular-weight heparin field.”

Mazen Darwazah, Hikma Vice Chairman and CEO of Emerging Markets said, “We are very pleased to be expanding our partnership with ROVI, adding this important cardiovascular product to our product portfolio in the MENA region. This partnership demonstrates the successful execution of our strategy to grow our biosimilar portfolio and improve patients' access to high-quality, affordable medicines.”